Novonesis A/s Class B · OMXCOP:NSIS_B
Novonesis A/s Class B — FY2023 Earnings Presentation
12 slides from Novonesis A/s Class B's earnings presentation, Feb 1, 2024
Slide 1: Conference call 12M 2023
Conference call 12M 2023 (unaudited) February 1, 2024
Slide 2: Forward Looking Statement
Forward Looking Statement Disclaimer This presentation and its related comments contain forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limite
Slide 3: 6% organic sales growth in Q4; 5% for the full year
6% organic sales growth in Q4; 5% for the full year with solid margins and free cash flow generation Sales and financial performance (12M) Key events and Novonesis • 5% organic sales growth with flat volumes. Q4 at 6% with ~4% pricing and ~2% volume growth. • 18 product launches of which 7 were publ
Slide 4: Household Care
Household Care 28% of sales Strong performance supported by price, innovation and penetration • Organic 12M sales growth y/y: 5% (Q4 y/y: 10%). • Pricing had a positive impact on growth. Organic sales performance (y/y) • Growth in developed markets driven by innovation, more than offsetting the nega
Slide 5: Food, Beverages & Human Health
Food, Beverages & Human Health 22% of sales Soft performance driven by destocking • Organic 12M sales growth y/y: -2% (Q4 y/y: -4%). • Negative YTD impact of roughly 2 percentage points from Q1 comparator effect. Organic sales performance (y/y) 16% • Underlying development driven by pricing and Food
Slide 6: Bioenergy
Bioenergy 25% of sales Strong performance driven by innovation and penetration • Organic 12M sales growth y/y: 23% (Q4 y/y: 20%). Organic sales performance (y/y) • Growth mainly driven by innovation and penetration in North America supported by solid market fundamentals including a 2% increase in U.
Slide 7: Grain & Tech Processing
Grain & Tech Processing 13% of sales Negative development driven by Tech • Organic 12M sales growth y/y: -6% (Q4 y/y: 2%). Organic sales performance (y/y) • Tech declined due to significantly lower sales of enzymes for Covid-19 test kits and a much softer-than-expected textile market. • Grain impact
Slide 8: Agriculture, Animal Health & Nutrition
Agriculture, Animal Health & Nutrition 12% of sales Performance driven by Animal Health & Nutrition • Organic 12M sales growth y/y: 3% (Q4 y/y: -7%). Organic sales performance (y/y) • Performance driven by Animal Health & Nutrition. • Agriculture was soft, impacted by destocking and a volatile end-m
Slide 9: Solid performance in line with expectations
Solid performance in line with expectations • Organic sales growth 12M y/y: 5% (Q4 6%). • Gross margin at 54.3% and supported by price increases and productivity 12M 12M Q4 Q4 improvements however not fully compensating higher input costs. 2023 2022 2023 2022 • Q4 with year-on-year and Q4/Q3 improve
Slide 10: Key milestones for the combination with Chr. Hansen
Key milestones for the combination with Chr. Hansen Announcement The Danish Tax Cees de Jong Exemption The U.S. Extraordinary Regulatory Leadership Interim Regulatory Regulatory Completion of of combination Assessment elected Chair document antitrust General approval in Team dividend approval in app
Slide 11: Expected timeline 2024
Expected timeline 2024 Closing announcement Annual Report 2023 Q1 trading update EGM Capital Markets Day AGM FY results update Jan. 29 Feb. 1 Feb. 8 Mar. 31 Apr. 30 May 3 Jun. 18 Novonesis numbers provided no later than March 31 Proforma revenue and org. growth Key financial proforma numbers Outlook
Slide 12: A new era of biosolutions
A new era of biosolutions